{
    "id": "26919897",
    "text": "Darglitazone (previously known as CP 86325-2) is a member of the class of drugs and an agonist of peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as . Its development was terminated on November 08, 1999. ==Synthesis== Synthesis of darglitazone == References == Category:Abandoned drugs Category:Oxazoles Category:Thiazolidinediones ",
    "title": "Darglitazone"
}